Mitomycin C inhibits recurrent Avellino dystrophy after phototherapeutic keratectomy.

Abstract

PURPOSE:

To report 4 patients with Avellino corneal dystrophy (ACD) who were treated with 0.02% mitomycin C (MMC) during phototherapeutic keratectomy (PTK).

METHODS:

ACD was confirmed by polymorphism of the exon region in the BIGH3 gene using polymerase chain reaction followed by DNA sequencing analysis. Three patients with recurrent ACD and 1 patient with primary ACD underwent PTK. Intraoperative 0.02% MMC was applied topically with a soaked microsponge.

RESULTS:

There was no recurrence of ACD in the heterozygotes, but there were recurrences with best-corrected visual acuity of 20/30 in the 2 homozygotes.

CONCLUSION:

Intraoperative use of topical 0.02% MMC in conjunction with PTK may prevent or delay the recurrence of ACD for at least for 1 year.

• Authors: Tae-im Kim, Jhang Ho Pak, Ju-byung Chae, Eung Kweon Kim, Hungwon Tchah
• Journal: Cornea (Cornea) Vol. 25 Issue 2 Pg. 220-3 (Feb 2006) ISSN: 0277-3740 [Print] United States
• PMID: 16371787 (Publication Type: Case Reports, Journal Article)

Chemical References

• Nucleic Acid Synthesis Inhibitors
• Ophthalmic Solutions
• Mitomycin

Topics

• Adult
• Corneal Dystrophies, Hereditary (drug therapy, pathology, surgery)
• Female
• Follow-Up Studies
• Humans
• Intraoperative Period
• Lasers, Excimer
• Male
• Middle Aged
• Mitomycin (administration & dosage, therapeutic use)
• Nucleic Acid Synthesis Inhibitors (administration & dosage, therapeutic use)
• Ophthalmic Solutions
• Photorefractive Keratectomy
• Secondary Prevention
• Visual Acuity